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Abstract 
Degree project, Programme in Medicine 
HPV Prevalence in HIV infected and Healthy Rwandan Women 
Hanna Erlandsson, University of Gothenburg, Sweden 2016 
 
Background 
Cervical cancer is the leading cause of cancer death among women in Rwanda, thus making it 
essential to map out the prevalence of different human papillomavirus (HPV) types. Mass 
vaccination programs of school girls have been enrolled in Rwanda covering HPV16 and 
HPV18. In Sweden, HPV16 and HPV 18 stand for 70 % of all cervical cancers. In Rwanda, 
the prevalence of HPV strains in the population is not known. Here we assessed the 
prevalence of different HPV strains in HIV patients and a healthy control group of patients in 
Rwanda.  
 
Aim 
To assess the prevalence of HPV infection in healthy and HIV infected women in Rwanda.  
 
Methods 
Cervical specimens and data were obtained from 200 healthy and 200 HIV-infected Rwandan 
women. The prevalence of different HPV strains among the study participants was analysed. 
The patients were tested for 39 different HPV strains.  
  
Results 
The prevalence of any HPV infection was higher among HIV positive-women than HIV- 
negative women (27.7% vs.10.5%) (P <0.001, OR 3.26, CI 1.81-5.87), and so was the 
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prevalence of ‘high-risk’-HPV (HR-HPV) (17.5% vs. 4.3%) and the ratio of HR-HPV out of 
any HPV (63.2% vs. 41.2%). The prevalence of multiple HPV infections was also higher 
among HIV-positive women (8.7% vs. 1.2%, P <0.001). The most common HR-HPVs were 
HPV16 (29.4%) and HPV52 (11.8%) in the HIV-negative group, and HPV52 (22.8%), 
HPV16 (17.5%), HPV31 and HPV58 (7.0%) in the HIV- positive group. HPV52 was 
common as a co-infection in the HIV-positive group.  
 
Conclusions 
The results show that HPV16 and HPV18 may not be as common in Rwanda as in Western 
countries, and that other carcinogenic HPV strains are more prevalent. Hence, the present 
findings should be taken into consideration for future vaccination programs in Rwanda.  
 
Keywords: HPV, cervical cancer, HIV, Rwanda  
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Introduction  
 
The burden of cervical cancer:  globally, in Sub-Saharan Africa, and in Rwanda  
Cervical cancer is the third most common cancer in women in the world accounting for 9% of 
all female cancers and 9% of all cancer deaths in women (1). In Sub-Saharan Africa, cervical 
cancer is the most common cancer form among women. Cervical cancer is caused by the 
sexually-transmitted human papillomavirus (HPV) (2, 3). A prevalence study in South Africa 
showed that 74% of all women attending a public sector in primary care were HPV positive 
and 54% of the infections were classified as ‘high-risk’ HPV (HR-HPV) infections (4).  
 
In Rwanda, cervical cancer is the leading cause of cancer death among women. In 2008, 
Rwanda had 34.5 cervical cancer cases and 25.5 cervical cancer deaths per 100,000 
inhabitants (5). Company-sponsored vaccination programmes have been enrolled in Rwanda 
since 2013. It is predicted that vaccination of young girls naive to HPV with HPV-16/18 
vaccine may result in a reduction in the number of cervical cancer cases and deaths in the 
future. Furthermore, it may also protect against other HPV types than HPV16 and HPV18 (6, 
7). However, studies show that vaccination against HPV-16/18 may not be sufficient since 
many other HPV strains than the HPV-16/18 are prevalent in cervical HPV infections in 
Africa (8). It is of utmost interest to further investigate these aspects that may have 
significance for primary prevention against cervical cancer, i.e. when developing a 
vaccination programme as well as a screening programme adjusted to Rwandan women.  
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Human papillomaviruses (HPVs) and cervical cancer  
Human papillomaviruses (HPVs) are a group of double-stranded circular DNA viruses (8). 
The HPVs constitute five out of sixteen genera of papilloma viruses (PVs): alpha, beta, 
gamma, mu and nu (9). HPV is the etiological agent of anogenital cancers and about 30-40% 
of oropharyngeal cancers. There are more than 150 HPV genotypes characterized and the 
types associated with anogenital cancer are of alpha-PV genus (10).  
 
The HPVs infect skin and mucosa and require the availability of a basal cell layer (cells able 
to proliferate), and infect the tissue commonly via microlesions of skin or mucosa. Some of 
the early expressed viral genes (E5, E6 and E7) stimulate proliferation in different ways. E5 
stimulates cell growth and prevents apoptosis following DNA damage, E6 degrades the pro-
apoptotic proteins p53 and BAK and activates telomerase, E7 degrades the retinoblastoma 
tumour suppressor protein (pRB) and stimulates the S-phase genes cyclin A and cyclin E. 
When E6 and E7 are expressed together they have a complementary and synergistic effect in 
immortalizing human cells (11, 12).  
 
HPV genotypes are normally divided into three groups. The HPV types mainly found in 
cervical and other anogenital cancers are referred to as ‘high-risk’ HPVs (HR-HPVs) and 
those found preferentially in genital warts and non-malignant lesions are referred to as ‘low-
risk’ HPVs (LR-HPVs) (12). The third group consists of HPV types that are considered as 
‘potentially high-risk’ HPV genotypes and includes HPV26, 53 and 66 (3). The most 
prevalent HR-HPV genotypes are 16, 18, 33, 45, 31, 58, 52, 35, 59, 56 and 51 (2, 13) while 
the main LR-HPV genotypes are 6, 11, 40, 42, 43, 44, 54, 61, 70, 72 and 81 (3). Of the HR-
HPV genotypes, HPV16 and HPV18 are responsible for 70% of all cervical cancers and about 
50% of all cervical intraepithelial neoplasia grade 3 (CIN3) (12). It is common to be infected 
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with multiple HPV strains simultaneously (3), although this is not associated with higher risk 
of developing cervical dyskaryosis compared to being infected with a single HPV strain (14).  
 
Ye et. al. observed a high prevalence of HPV52 and HPV58 in addition to HPV16 and 
HPV18 among women in the Zhejiang Province in southeast China (9). Data show that these 
strains are common also in Japan, Taiwan and Eastern Africa (15). These results show that the 
heterogeneity in HPV type-specific distributions needs to be considered when predicting the 
effects of current prophylactic vaccines as well as when forming the basis for the second-
generation vaccines targeted to specific regions (9, 16).   
  
Prevention: Methods of screening and vaccination  
The two leading strategies used to lower the incidence and mortality in cervical cancer are 
prevention through vaccination of young girls naive to HPV, and cervical cytological 
screening. The currently available vaccines provide protection against the HR-HPV genotypes 
16 and 18, as well as the LR-HPV genotypes 6 and 11 (Gardasil) or only 16 and 18 (Cervarix) 
(7). A 9-valent vaccine containing HPV6, 11, 16, 18, 31, 33, 45, 52, and 58 antigens was 
licensed by the US Food and Drug Administration (FDA) in 2014 (17) and by the European 
Medicines Agency (EMA) in June 2015 (18). HPV vaccination is an effective method for 
protection against HPV infection (6). Vaccination seems to induce a low degree of cross-
protection between HPV types (19), making the development of a polyvalent vaccine a 
priority in order to decrease the burden of cervical cancer. Cervical cancer screening is used 
to detect and treat precancerous lesions or early stage cancer in order to prevent surgery or 
radiotherapy demanding, or incurable cervical cancer from developing. A population-based 
cohort study in Sweden from 2012 concluded that screening is associated with improved 
chance of cure of cervical cancer (20).   
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The gold standard screening method is cervical cytology or Papanicolau, “Pap” smear. It is 
likewise the most frequently used method (21). A smear of collected cervical cells is stained 
and analysed so that lesions can be detected and staged through microscopy. In low-income 
countries, however, it is difficult to perform cytology due to the requirement of trained 
personnel and certified laboratories that can analyse the samples. Another method is to use 
HPV-DNA testing for cervical screening, thereby detecting high-risk strains of HPV using 
PCR.  HPV-DNA testing requires laboratory access - and the analysis is expensive and takes a 
minimum of seven hours to process. An alternative in low-income countries is careHPV 
which is a modified HPV test that is less resource demanding and more rapid. The least 
complicated screening method is visual inspection with acetic acid (VIA). Diluted acetic acid 
or vinegar is applied to the cervical mucosa. Abnormal cells, e.g. dysplastic cells and cancer 
cells, turn white while normal cells are unaffected. Using this inexpensive method, abnormal 
cells can be detected and treated almost immediately. Cytology is the method with the highest 
specificity while HPV-DNA has been shown to have the highest level of sensitivity (22). The 
World Health Organization (WHO) has presented guidelines for cervical cancer in a “screen-
and-treat programme”. The WHO expert panel has concluded that HPV-DNA testing 
followed by VIA and then treatment should be the standard method in resource-constrained 
settings. Where this is not available, VIA followed by treatment is the preferred screening 
approach (23).   
 
HPV prevention in Rwanda    
The Department of Obstetrics and Gynecology of Kigali University Teaching hospital, Kigali, 
Rwanda has recently implemented an online cervical cancer prevention course for all the 
resident doctors in Gynecology. The course is provided through an internet-based virtual 
training project specializing in cancer, called E-oncologia. Its main objective is to spread 
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knowledge about HPV and cervical cancer to health care professionals involved in cervical 
cancer prevention (24).   
 
Rwandan HPV vaccination and screening programme   
Rwanda is a low-income country in Sub-Saharan Africa with a population of 11.2 million and 
has become the first African country to develop and implement a national strategic plan for 
cervical cancer prevention, care and control. Through donation and concessional pricing of 
the HPV vaccine Gardasil, integration of the HPV vaccination has been enrolled into 
Rwanda’s national immunization programme starting 2011. All girls in the 6th grade received 
the vaccine, covering more than 93% and also reaching out-of-school girls. Beside the 
vaccination programme, Rwanda has initialized a screening programme which begun in 2013. 
The intention is that the detection pathway should include testing for HPV DNA followed by 
visual inspection with acetic acid (VIA) and, when necessary, colposcopy and biopsy. 
However, at present the screening method used in the clinical practice is cytology. The 
cytology screening is free and includes HIV-positive women aged 30-50 years and HIV-
negative women aged 30-45 years recruited to health centres. Development of the screening 
programme also relies on training of doctors and specialized nurses to perform the test and 
interpret the samples, a very important step in order to expand the screening process 
nationwide (5, 22, 25).  
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Figure 1. Cervical cancer screening and treatment in Rwanda, 2013. Figure originally from Binagwaho et. al. 
(5) with kind permission. 
HIV= human immunodeficiency virus; HPV=human papillomavirus; LEEP= loop electrosurgical excision 
procedure; VIA= visual inspection with acetic acid. 
 
Challenges for cervical cancer prevention in Rwanda  
The HPV vaccination and screening programme is an important step on the way to 
prevention, care and control of cervical cancer in Rwandan women.  Nevertheless, a 
considerable amount of work remains before similar results when it comes to incidence and 
mortality can be seen in Rwanda as in industrial countries. In order for a nationwide 
vaccination programme to be successful it requires collaboration between public and private 
institutions as well as a well-established vaccine delivery system (25). A company-sponsored 
vaccine and screening programme is also fragile due to the dependence on the company’s 
good will. In 2012, the Global Alliance for Vaccination and Immunization (GAVI) initialized 
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funding of the HPV vaccine in some countries, and in 2014, Rwanda switched from 
manufacturer- to GAVI-support (17).  
A limiting factor for a nationwide implementation of the cervical screening programme is the 
lack of pathologists in Rwanda, with only three general pathologists in 2012 for a population 
of 11 million (26). In comparison, there were 189 fulltime pathologists in Sweden in 2010 for 
a population of 9.4 million (27), a number regarded as insufficient (28). The present screening 
programme for cervical cancer in Rwanda relies on women seeking health care for 
gynaecological examination, which results in a vulnerable system where only a minority of 
the population participates in the screening programme. In order for a screening programme 
to be successful it must be affordable and have accessible referral sources, treatment and 
follow-up (29) in addition to increased knowledge in the population.  
 
Risk factors and limitations for optimal management of cervical cancer  
In addition to HPV infection, other risk factors for developing cervical cancer have been 
identified and include high parity, oral contraceptives (30) and smoking (31). Further risk 
factors identified in African settings are genital hygiene, alcohol use and male sexual behavior 
(32).  
 
It is common that women in Sub-Saharan Africa who develop cervical cancer do not receive 
treatment, which is primarily due to financial and/or geographical lack of access to health care 
(33). The mortality in cervical cancer is significantly higher in Sub-Saharan Africa than in 
high-income countries, i.e. in 2002 the survival rate was 21% compared with 66% in Western 
Europe and 70% in the United States (34). A number of reasons for  the low survival rate have 
been listed: poor access to medical facilities, poor nutrition and co-morbidities, e.g. malaria, 
anemia (35) and HIV-infection, late presentation with the disease, large tumours at diagnosis, 
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poor quality  health care service, high rate of loss of follow-up and women not completing 
treatment due to barriers imposed by poverty (33). 
 
HPV under concomitant HIV infection   
HIV infection increases the risk of developing cervical cancer. In fact, it has been shown that 
HIV alters the natural history of HPV infection with decreased regression rates of cervical 
lesions and more rapid progression to high-grade and invasive lesions (36). Alternatively, 
HPV infection may predispose an individual to HIV infection and facilitate the progression of 
HIV (37). In Rwanda, the official numbers on prevalence of HIV-infection is estimated to 
2.8% (38).  Among HIV-positive women in Rwanda, 46% are positive for carcinogenic HPV 
subtypes (39). Studies in Rwanda show that 9% of HIV+/HPV+ women are diagnosed with 
CIN grade 3 (40). Studies have observed a significantly higher prevalence of CIN in HIV-
infected than in uninfected women, identifying both HPV infection and the immunodeficiency 
as strong independent risk factors for abnormal cytology (41).  HIV infected women also tend 
to develop cervical cancer at an earlier age than uninfected women (42). The importance of 
cervical screening and management guidelines for HIV positive women is evident (43). HPV 
genotypes 16 and 18 are responsible for 70% of cervical cancers; however, this distribution is 
somewhat different in HIV-infected women, with other HR-HPVs more prevalent than in the 
general population. Furthermore, the HIV-positive women are more often presenting with 
multiple HPV strings. A study on HIV-positive women living in Europe, the majority of 
whom were of African descent, observed a high prevalence of HPV52 (19.8%) and 
HPV31/35/51/58 (12.1%), compared to HPV18 (14.6%) and HIV16 (9.5%). The same study 
concluded that 79% of the women in the study would be covered by the 9-valent vaccine 
against HPV (44). 
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Aim  
 
The present Master thesis was performed within the project “Immunological responses in the 
cervix in response to HPV infection in a cohort of HIV infected and non-infected Rwandan 
women” sponsored partly by SIDA. The overall aim of the SIDA-sponsored project is to 
assess whether immunological differences exist between women that develop chronic HPV 
infection and women who eradicate their HPV infection. The aim of the present Master thesis 
was to assess the prevalence of different HPV infections in a cohort of HIV-infected women 
and a cohort of healthy women in Rwanda.  
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Material and Methods  
 
Study description  
A cohort of women seeking voluntarily for ThinPrep Pap (“Pap”-smear) test (cohort A; 200 
patients) were recruited at the Department of Obstetrics and Gynaecology of Kigali 
University Teaching Hospital, Kigali, Rwanda and Butare University Teaching Hospital, 
Butare, Rwanda, where patients with cervical cancer are generally admitted. Additionally a 
cohort of HIV infected women (cohort B; 200) were recruited at the HIV-clinics of the two 
hospitals. The nurse who normally receives patients was the one to recruit the patients 
according to the study protocol. The recruitment process was performed continuously and for 
the voluntary cohort it relied to a great extent on information spread by word of mouth. 
Additionally, recruitment was supplemented by women who sought health care at the 
gynaecological clinics in Butare or Kigali for other reasons than for cervical cancer screening. 
The data used for the master thesis was collected during the period of July to October 2015 at 
the time of enrolment in the larger study. The study participants did not have to finance 
partaking in the study; however, they had to cover other costs related to the first consultation. 
The study participants financed the prescribed additional laboratory tests, e.g. HIV test, 
performed at the first visit, and were later compensated with 5000 RWF for time and travel 
costs related to the study.   
 
After having answered a questionnaire, the participants underwent a pelvic examination 
including a ThinPrep Pap test. The gynaecological examination and sampling was performed 
by a physician at respective clinic. The ThinPrep tests were then analysed in Sweden for 
cytology, identifying patients with CIN or cancer and additionally screened for HR-HPVs 
using RT-PCR. Patients that were positive for HPV were classified as HPV-positive and other 
15 
 
patients were classified as HPV-negative. The HPV types tested for are listed in Table 1 (3, 
45). During the same visit the participants were requested having additional laboratory exams 
performed by a laboratory technician, including tests for HIV and other sexually transmitted 
diseases (STDs) such as Chlamydia, Gonorrhoea, Hepatitis B and C, Trichomonas and Herpes 
Simplex 2 (HSV-2).  
 
Table 1. HPV strains tested for.  
HPV class HPV genotype 
High risk 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82 
Low risk  6, 11, 30, 40, 42, 43, 54, 61, 70, 74, 81, 86, 87, 89, 90, 91  
Potentially high risk  26, 53, 66, 67, 69, 70, 83 
*In this study, HPV74, 86, 87, 89, 90, and 91 were considered ‘low-risk’ HPVs -however, more studies are 
required to evaluate the cancerogenicity of these HPV genotypes.  
 
The master thesis includes compiled data from the two cohorts where an analysis of the 
available data was performed regarding the patients’ HPV status, i.e. if infected with HPV and 
which HPV strain/-s. The women from the two cohorts were divided into two new groups for 
comparison and statistical analyses based on the HIV test results: HIV-positive and HIV-
negative. Thirty-two participants from the voluntary cohort were excluded because they were 
not tested for HIV at the time of the cervical screening. Furthermore six patients first 
belonging to the voluntary cohort were diagnosed as HIV positive and were therefore 
transferred to the HIV-positive group.  
Participants – inclusion and exclusion criteria  
Women visiting gynaecologic outpatient departments at Kigali or Butare Teaching Hospitals 
were invited to participate in the study. Women agreeing to participate signed an informed 
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consent form and were informed about the study both orally and by written information. If a 
candidate met the inclusion criteria, a pelvic examination was performed and a cervical 
sample was taken for cytology and HPV testing.  
 
Participants in the voluntary cohort were women considered eligible if they were 17 years of 
age or older, were voluntarily seeking cervical cancer screening service, were literate in 
Kinyarwanda, English or French, had completed and signed the Informed Consent Form and 
had no plan to relocate in the next two years. Participants in the HIV cohort had the same 
inclusion criteria as those in the voluntary cohort with the additional requirement of being 
HIV infected.  
 
Patients were excluded from either cohort if they had any known concurrent disease likely to 
limit life expectancy to less than 24 months, had any other factors suggesting inability to 
comply with the study protocol, were diagnosed with cervical cancer before or at the time of 
inclusion, had known or visible present vaginal or cervical infection besides HPV at the time 
of inclusion, or had any condition or major comorbidity that the study investigators believed 
would compromise the patient's ability to comply with the requirements of the study.  
Data handling  
The main identifier (the National Identification number and names) was hidden in a database 
only accessible to the investigators and personnel within the project. All samples were coded 
so that the biomarker data and analysis of the patients could not be connected to an individual 
patient.  
Clinical examination and laboratory analyses  
A standard cervical specimen was collected. Smears were obtained as standard procedures by 
inserting a cytobrush in the endocervical canal and rotating it twice at 360°. Some of the 
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samples were aliquoted for storage at -80°C and then transported to the University of 
Gothenburg, Sweden, for further cytology, and to Karolinska Institutet, Stockholm, Sweden, 
for HPV DNA and genotyping test. The remaining analyses for sexually transmitted diseases 
were performed at the Kigali University Teaching Hospital (KUTH) clinical laboratory. HPV 
expression was analyzed with RT-PCR.  
 
Ethics  
 
The study has been approved by the Ethical Review Board of the University of Gothenburg 
and the University of Rwanda. It was possible for the patient to withdraw from the study at 
any time without stating a reason for it, and this was explained before inclusion in the study. 
We also informed the patients about confidentiality and the handling of collected data.  
 
Data collection procedures/Variable analyses/Statistical methods  
 
All data was collected in Rwanda during 2015 as described above. Analyses were done in 
SPSS Version 21 and Microsoft Excel 2010. Statistical analyses for P-value, odds ratio and 95 
% confidence limits were done by Chi-square test, Fisher’s Exact test, binary logistic 
regression analysis, ordinal scale regression and t-test. To test for differences between HIV-
positive and HIV-negative patients a Chi-square test and Fisher’s Exact test was performed. 
Binary logistic regression analysis was used to calculate odds ratio and confidence intervals. 
Ordinal scale regression was used to calculate p-value and confidence intervals for multiple 
HPV infections in the groups. A p-value of 0.05 was considered statistically significant.  
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Results  
 
Cytological and HPV data were available for all 400 women in the study.  Missing data for 
HIV status was the reason for excluding thirty-two of the women in the voluntary cohort. 
Furthermore six of the women in the voluntary cohort tested positive for HIV, and were thus 
included in the HIV-positive group when analysing the data. This resulted in 162 women 
included in the HIV-negative group and 206 women in the HIV-positive group. HIV-positive 
women were older, i.e. the mean age was 45.6 compared with 39.9 for HIV-negative women 
(P<0.001), HIV-positive patients had undergone cervical cancer screening to a greater extent 
than voluntary patients, i.e., 27.7% vs. 7.4% (P<0.001) (Figure 3). HIV patients had their 
sexual debut at an older age than HIV-negative patients, i.e., 22.6 vs. 19.9 (P<0.001), and had 
had a higher number of sexual partners, 3.8 vs. 2.04 partners (P<0.002). Characteristics for 
the participants are displayed in Table 2.  
 
The prevalence of HPV infection was higher among HIV-positive women than HIV-negative 
women (27.7% vs. 10.5%) (P <0.001, OR 3.26, CI 1.81-5.87) (Figure 2), and so was the 
prevalence of HR-HPV (17.5% vs. 4.3%) (P <0.001, OR 4.69, CI 2.03-10.84) (Figure 6, 7, 8). 
The percentage of HR-HPV out of any HPV was also higher, although not statistically 
significant (63.2% vs. 41.2%, P 0.248). The prevalence of multiple HPV infections was 
higher among HIV-positive women than HIV-negative women (8.7% vs. 1.2%, P <0.001) 
(Figure 9, 10).The most common HR-HPVs were HPV16 (29.4%) and HPV52 (11.8%) in the 
HIV-negative group (Figure 11), and HPV52 (22.8%), HPV16 (17.5%), HPV31 and HPV58 
(7.0%), and HPV18, HPV39, HPV68 (3.5%) in the HIV-positive group (Figure 13). The 
distribution of HR-HPV strains is shown in Figure 15 and Figure 17. In the HIV-positive 
group, seven out of the thirteen patients (54%) infected with HPV52 were also infected with 
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other strains of HPV, in comparison to the patients infected with HPV16 where five out of ten 
patients (50%) were also infected with other strains of HPV.  
 
 
 
 
Figure 2. HPV status (any HPV or negative) stratified by HIV status. 
HPV; human papillomavirus. The total number of patients in each group was 162 in the HIV-negative group and 
206 in the HIV-positive group. Any HPV includes all of the HPV strains tested for, explained in Table 1. The 
prevalence of any HPV was 10.5% (17/162) in the HIV-negative group, and 27.7 % (57/206)  in the HIV-
positive group. Binary scale regression analysis was used to calculate p-value, confidence interval (CI) and odds 
ratio (OR) (P <0.001, OR 3.26, CI 1.81-5.87).   
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Discussion with Conclusions and Implications 
 
The present study shows that HPV infections are common among women, particularly among 
HIV patients. In contrast to the situation in Europe, the prevalence of HPV16 and HPV18 is 
not as high in comparison to other HPV strains when it comes to HPV-related cervical 
infections in the Rwandan women in this study. Especially HPV18 was not as frequent as the 
prevalence observed in Western countries (46). According to the results from this study, 86% 
of the women with HR-HPVs would be covered by the new 9-valent vaccine. Similar 
tendencies have been observed in other studies, with HPV16 and HPV18 being 
underrepresented in HIV-positive women compared to the general population, and HPV52 
being more frequent, especially in women from Africa (47). 
 
There are few available data on HPV-DNA prevalence in African women, and the populations 
studied have not been comparable. The lowest prevalence was observed in a study on women 
without cervical cancer in South Africa, with a prevalence of 12% (48), while the highest 
prevalence, 46%, was observed in women attending clinics for antenatal care or general 
genital symptoms in Gabon (49). A study on Rwandan women from 2009 observed a 
prevalence of HPV infection of 13% in HIV-negative women. This study showed a HPV-
DNA prevalence of 10.4% in the HIV-negative group. This prevalence number is slightly 
lower than what has been observed in previous studies on women in Sub-Saharan Africa. 
Potential reasons for this disconcordance are discussed further down. The result of the present 
study is an important contribution to the mapping of HPV-DNA prevalence in women in 
Rwanda. However, it is still essential with larger studies to assess the HPV-DNA prevalence 
in Rwandan women, as well as in African women in general.  
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The results from this study are in line with previous studies, demonstrating differences in 
prevalence of HPV genotypes in HIV patients compared to HIV-negatives. The most common 
HR-HPVs were HPV16 (29.4%) and HPV52 (11.8%) in the HIV-negative group, while 
HPV52 (22.8%) and HPV16 (17.5%) were the most common HPV strains in the HIV-positive 
group. Other common HPV infections were HPV31 and HPV58 in the HIV-positive group. 
At present, the Rwandan vaccination programme includes Gardasil only covering HPV16 and 
HPV18 among HR-HPV, making the coverage incomplete. The HR-HPVs that we have 
identified as the most common among Rwandan women in this study would all be covered by 
the 9-valent vaccine. The 9-valent vaccine has been shown to have an efficacy of 96.7%  
against HPV 31, 33, 45, 52 and 58 associated high-grade cervical, vulvar, and vaginal lesions. 
The vaccine demonstrated also an equivalent level of antibody response to HPV 6, 11, 16, and 
18 as the quadrivalent vaccine Gardasil (17, 18).  
 
Noteworthy is that the division of HPV genotypes into groups is based on results from 
previous studies examining HPV genotypes present together with cervical cancer or 
precancerous lesions (3). The cancerogenicity of some of the most common HPV strains is 
well-established; however, further studies are required in order to distinguish the 
cancerogenicity of some of the less frequently occurring HPV strains (45). First when this is 
clarified, it is possible to fully evaluate the effect of new broader vaccines.  
 
The study observed a significantly higher HPV-DNA prevalence in the HIV infected women 
compared to the uninfected women, which is consistent with previous findings (47). The 
prevalence was 27.7% for any HPV, 17.5% for HR-HPV, and 8.7% for multiple HPV types in 
the HIV positive group. The aforementioned 2009 Rwandan study showed a higher 
prevalence of infection with HPV among HIV-positive women than this study (39). The 
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difference in prevalence could result from differing CD4-cell counts, HIV viral loads, age 
distributions, sexual behaviours etc. The observed higher prevalence of multiple HPV-
infections among HIV-positive women than among HIV-negative women is in line with 
results from previous studies from Rwanda (8). This finding indicates that in addition to 
alternation of the natural history of HPV infection with decreased regression rates of HPV 
infection and more rapid progression to high grade and invasive lesions, HIV infection might 
facilitate multiple HPVs to infect the cervical mucosa, possibly by affecting the immune 
response in the cervix. 
 
One interesting finding in the HIV cohort was that seven out of the thirteen patients infected 
with HPV52 were also infected with other strains of HPV. This finding could potentially 
indicate that an HPV52 infection causes vulnerability in the infected woman which facilitates 
further HPV infections of the cervical mucosa. This finding suggests a need for future studies 
designed to assess the characteristics of different HPV strains. 
 
Studies acknowledge several obstacles to cervical cancer prevention and treatment in Sub-
Saharan countries, including low level of cervical cancer awareness and understanding, lack 
of effective and high quality screening, financial constraints and poor knowledge of risks and 
treatment options (50). In Rwanda, the resources for treatment of advanced cervical cancer are 
limited, thus making it even more important with a well-functioning prevention strategy 
through vaccination and screening. Furthermore it is of utmost importance to target the above 
mentioned obstacles to cervical cancer prevention and treatment in order to optimize the 
Rwandan cervical cancer prevention programme.  
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The results on HPV prevalence observed in this study are representable for the HIV-infected 
female Rwandan population, and can be used to help evaluate which approach to cervical 
cancer prevention among HIV-positive women is most effective. Regarding the HIV-negative 
group, the study population did not provide a large enough material to be able to evaluate the 
prevalence of different HPV strains in the general population. Furthermore, the participants 
cannot be considered representative for the entire population due to the design of the study. 
The recruitment process of the voluntary cohort was carried out to a great extent through word 
of mouth, and through women who had already sought care at a gynaecological clinic. It is 
possible that the knowledge about HPV infection and cervical cancer is higher in a group of 
women who voluntarily seek health care at a gynaecological clinic than the average in the 
population. The fact that the study was performed at University Hospitals in the two largest 
cities in Rwanda, Kigali and Butare, in addition to the inclusion criteria of being literate in 
either Kinyarwanda, English or French, may also have contributed to a selected group of 
women with a lower prevalence of HPV infection than the average in the female Rwandan 
population. The HIV cohort was recruited to the study during planned visits to the HIV-clinic 
which postulates a better generalisability for the female HIV population in Rwanda.  
 
In addition to the possibility that the recruited women in the voluntary cohort are more likely 
to have a higher awareness about cervical cancer and screening than the general population, 
the aforementioned aspects might also affect factors that may have an impact on the risk for 
HPV-infection and cervical cancer. Potential affected aspects include propensity to seek 
health care, age at first sexual intercourse, number of sexual partners, plus co-factors for 
developing cervical cancer, e.g. smoking, use of hormonal contraceptives, and other STIs. 
 
24 
 
This study did not examine the potential influence of other sexually transmitted diseases 
(STDs) in addition to HIV on HPV infection and cervical cancer. For future studies it would 
be of great interest to investigate the connection between HPV infection and additional STDs 
other than HIV, e.g. Chlamydia, Gonorrhoea, HSV-2, Hepatitis B and C, and Trichomonas. It 
would also be interesting to assess whether sexual behaviour has the most significant impact 
on the prevalence of HPV infection-, or if concomitant STDs may facilitate the transmission 
and/or persistence of an HPV infection by altering the immune response.  
 
It would be desirable to perform larger studies on HPV-DNA prevalence in the female 
Rwandan population, as well as studies on HPV prevalence in the male population, since 
HPV infection also causes the majority of anal cancers, penile cancers, oropharyngeal 
cancers, and genital warts. The chain of transmission is also maintained if boys are not 
included in the vaccination programme (51). Including men in a HPV-DNA prevalence study 
would be helpful when evaluating the cost-effectiveness of the potential inclusion of boys in 
the Rwandan vaccination programme (52). The European Centre for Disease Prevention and 
Control (ECDC) has concluded that universal coverage of both males and females would be 
the most effective strategy to prevent HPV-related morbidity, since it both prevents HPV-
related conditions in men as well as provides protection against cervical cancer in women 
through herd immunity (53).  
 
The aim of the larger study, to assess the immunological response of the cervix in response to 
HPV infection, can contribute to the understanding of the natural course of HPV infection, 
and possibly highlight potential risk groups in the female Rwandan population that might 
need to be more intensely examined in the recently initiated cervical cancer screening 
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programme. Individualised treatment and screening procedures could potentially be realised 
within a foreseeable future based on the patients’ immunological profiles.  
 
This study has identified HIV-infected women as one of the risk groups that would most 
likely benefit from more intense cervical cancer prevention strategies. Considering the high 
prevalence of HPV52, HPV31 and HPV58 in the HIV-positive group, a majority of the 
cancerogenous HPV infections are not covered by thevaccine currently used in the Rwandan 
vaccination programme. However, the prevalence of HIV in the Rwandan adult population is 
only 2.8% (38). This implies that further studies and analyses are required in order to 
conclude if implementation of a new broader vaccine for all young girls would be the most 
cost-efficient alternative for cervical cancer prevention among HIV-positive women, or if 
more intense screening for this risk group is a more efficient approach.  
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Populärvetenskaplig sammanfattning  
HIV-prevalens hos HIV-infekterade och friska kvinnor i Rwanda 
 
Livmoderhalscancer orsakas av det sexuellt överförbara viruset humant papillomvirus (HPV). 
I Rwanda är livmoderhalscancer den främsta orsaken till cancerdöd bland kvinnor. 2011 
inleddes ett företagsfinansierat vaccinationsprogram i Rwanda där unga flickor vaccineras 
med Gardasil som skyddar mot de mest cancerframkallande HPV-typerna HPV16 och 
HPV18. Detta förväntas resultera i en minskning av förekomsten av livmoderhalscancer i 
framtiden. Studier har dock visat att vaccination mot HPV-16/18 kan vara otillräckligt 
eftersom flera andra cancerframkallande HPV-typer är vanligt förekommande vid HPV-
infektion i livmoderhalsen hos kvinnor i Afrika.  
 
Den aktuella studien utfördes i Rwanda där vi undersökte förekomsten av HPV-infektion och 
cellförändringar i livmoderhalsen hos 200 kvinnor med HIV och 200 friska frivilliga kvinnor. 
Våra resultat visar att HIV-positiva kvinnor oftare var infekterade med HPV än HIV-negativa 
patienter och andelen med mer cancerframkallande HPV-arter var högre bland patienter med 
samtidig HIV-infektion. Dessutom var det vanligare bland HIV-infekterade än bland HIV-
negativa att vara infekterad av flera HPV-typer samtidigt. 
 
Vår studie visar också att HPV16 och HPV18 är betydligt ovanligare i Rwanda än i 
Västvärlden. Enligt våra resultat var HPV52 och HPV16 de cancerframkallande HPV-arter 
som förekom mest frekvent, och bland HIV-infekterade var även HPV31 och HPV58 vanligt 
förekommande. Detta skulle kunna innebära att det vaccin som används idag i Rwanda ger ett 
inkomplett skydd mot livmoderhalscancer. På marknaden finns idag ett nytt vaccin 
27 
 
tillgängligt som skyddar mot HPV16, HPV18, HPV31, HPV33, HPV45, HPV52 och HPV58 
vilket skulle kunna ge ett skydd mot de vanligast förekommande HPV-arterna i Rwanda.  
 
Det är dock av stor vikt att undersöka om man i framtiden kan införa vaccinationer som bättre 
täcker de vanligaste HPV-arterna som förekommer i Rwanda. På detta sätt kan man på sikt 
minska dödligheten i livmoderhalscancer i ett land där terapi mot sjukdomen också är mycket 
begränsad. För att ytterligare minska förekomsten av långt gången livmoderhalscancer behövs 
ett fungerande screeningprogram som möjliggör tidig upptäckt och behandling av förstadier 
till cancer och behandlingsbar cancer.  
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Tables and Figures  
 
Table 2. Baseline characteristics of the participants stratified by HIV status.  
 
 
  
HIV status N* Minimum Maximum Mean Std. Deviation P-value 
Positive 
Age at first sexual intercourse 205 7 33 19,87 4,156 P<0.001 
Number of sexual partners 206 1 55 3,80 6,565 P=0.002 
Number of spontaneous or voluntary 
abortions 
206 0 5 ,48 ,807 P=0.397 
Number of live births 206 0 8 3,56 1,909 P=0.023 
Participant age in years 206 26 66 45,59 7,826 P<0.001 
Negative 
Age at first sexual intercourses 159 12 42 22,55 5,473 P<0.001 
Number of sexual partners 159 1 43 2,04 3,555 P=0.002 
Number of spontaneous  or voluntary 
abortions 
159 0 8 ,57 1,117 P=0.397 
Number of live births 159 0 9 3,07 2,179 P=0.023 
Participant age in years 162 23 70 39,94 9,648 P<0.001 
 
*The total number of patients (N) in each row is based on the number of patients for whom there were data on 
the questions at enrolment. T-test was used to calculate P-values on the difference between the HIV-negative and 
HIV-positive group.  
 
 
 
Figure 3. Previous screening for cervical cancer stratified by HIV status.  
The total number of patients in each group was 162 in the HIV-negative group and 206 in the HIV-positive 
group. 27.7% had previously been screened for cervical cancer in the HIV-positive group, vs. 7.4% in the HIV-
negative group. ChiSquare test was used to calculate a P-value (P<0.001). 
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Figure 4. HPV status among HIV-negative.  
HPV; human papillomavirus. The total number of patients in each group was 162 in the HIV-negative group and 
206 in the HIV-positive group. Any HPV includes all of the HPV strains tested for, explained in Table 1. The 
prevalence of any HPV was 10.5% (17/162) in the HIV-negative group, and 27.7 % (57/206) in the HIV-positive 
group. Binary logistic regression analysis was used to calculate p-value, confidence interval (CI) and odds ratio 
(OR) (P <0.001, OR 3.26, CI 1.81-5.87). 
 
 
 
 
Figure 5. HPV status among HIV-positive.  
HPV; human papillomavirus. The total number of patients in each group was162 in the HIV-negative group and 
206 in the HIV-positive group. Any HPV includes all of the HPV strains tested for, explained in Table 1. The 
prevalence of any HPV was 10.5% (17/162) in the HIV-negative group, and 27.7 % (57/206)  in the HIV-
positive group. Binary logistic regression analysis was used to calculate p-value, confidence interval (CI) and 
odds ratio (OR) (P <0.001, OR 3.26, CI 1.81-5.87). 
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Figure 6. Comparison of human papillomavirus (HPV) class stratified by HIV-status. 
Low Risk Human Papillomavirus (LR-HPV) tested for were HPV6, 11, 30, 40, 42, 43, 54, 61, 70, 74, 81, 86, 87, 
89, 90, 91. High Risk (HR-HPV) tested for were HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82. 
Potentially High Risk (potentially HR-HPV) tested for were 26, 53, 66, 67, 69, 70, 83. Not shown in the chart is 
the HPV negative group, which constituted 89.5% of the HIV negative women, and 72.3% of the HIV positive 
women. . Binary logistic regression analysis was used to calculate p-value, confidence interval (CI) and odds 
ratio (OR) (P <0.001, OR 4.69, CI 2.03-10.84).  
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Figure 7. Comparison of human papillomavirus (HPV) class among HIV-negative women.  
HPV=human papillomavirus. NA=no HPV. Low Risk=’low-risk’ HPV. High Risk=’high-risk HPV. Potential 
High Risk=’potentially high-risk’ HPV. The HPV strains tested for are displayed in Table 1. The total number of 
patients was 162 in the HIV-negative group. Binary logistic regression analysis was used to calculate p-value, 
confidence interval (CI) and odds ratio (OR) (P <0.001, OR 4.69, CI 2.03-10.84). 
 
 
 
Figure 8. Comparison of human papillomavirus (HPV) class among HIV-positive women.  
HPV=human papillomavirus. NA=no HPV. Low Risk=’low-risk’ HPV. High Risk=’high-risk HPV. Potential 
High Risk=’potentially high-risk’ HPV. The HPV strains tested for are displayed in Table 1. The total number of 
patients was 206 in the HIV-positive group. . Binary logistic regression analysis was used to calculate p-value, 
confidence interval (CI) and odds ratio (OR)  (P <0.001, OR 4.69, CI 2.03-10.84). 
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Figure 9. Distribution of HPV infection (no HPV, one HPV or multiple HPV) among HIV-negative women.  
HPV=human papillomavirus. Multiple HPV= infected with >1 HPV strain. The HPV strains tested for are 
displayed in Table 1. The total number of patients was162 in the HIV-negative group. Ordinal scale regression 
analysis was used to calculate p-value (P<0.001).  
 
 
 
 
Figure 10. Distribution of HPV infection (no HPV, one HPV or multiple HPV) among HIV-positive women.  
HPV=human papillomavirus. Multiple HPV= >1 HPV strain. The HPV strains tested for are displayed in Table 
1. The total number of patients was 206 in the HIV-positive group. Ordinal scale regression analysis was used to 
calculate p-value (P<0.001).  
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Figure 11. Prevalence of Human papillomavirus (HPV) among HIV-negative.  
One patient can be infected with more than one HPV strain, hence adding up to more than 100%.  The 
percentages were calculated as positive cases (including both single and multiple HPV infections) out of the total 
number of patients with HPV infection in the HIV negative group (n=17). Other HR-HPV includes HPV31, 33, 
35, 39, 45, 51, 56, 58, 59, 68, 73, and 82. Other HPV includes HPV6, 11, 30, 40, 42, 43, 54, 61, 70, 74, 81, 86, 
87, 89, 90, 91, 26, 53, 66, 67, 69, 70, and 73.  
 
 
 
Figure 12. Prevalence (number of patients) of Human papillomavirus (HPV) among HIV-negative. 
One patient can be infected with more than one HPV strain. The total number of patients with HPV infection in 
the HIV-negative group was 17. Other HR-HPV includes HPV31, 33, 35, 39, 45, 51, 56, 58, 59, 68, 73, and 82. 
Other HPV includes HPV6, 11, 30, 40, 42, 43, 54, 61, 70, 74, 81, 86, 87, 89, 90, 91, 26, 53, 66, 67, 69, 70, and 
73.  
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Figure 13. Prevalence of Human papillomavirus (HPV) among HIV-positive. 
One patient can be infected with more than one HPV strain, hence adding up to more than 100 %.  The 
percentages were calculated as positive cases (including both single and multiple HPV infections) out of the total 
number of patients with HPV infection in the HIV-positive group (n=57).  Other HR-HPV includes HPV33, 35, 
39, 45, 51, 56, 59, 68, 73, and 82. Other HPV includes HPV6, 11, 30, 40, 42, 43, 54, 61, 70, 74, 81, 86, 87, 89, 
90, 91, 26, 53, 66, 67, 69, 70, and 73. 
 
 
 
Figure 14. Prevalence (number of patients) of Human papillomavirus (HPV) among HIV positive. 
One patient can be infected with more than one HPV strain. The total number of patients with HPV infection in 
the HIV-positive group was 57. Other HR-HPV includes HPV31, 33, 35, 39, 45, 51, 56, 58, 59, 68, 73, and 82. 
Other HPV includes HPV6, 11, 30, 40, 42, 43, 54, 61, 70, 74, 81, 86, 87, 89, 90, 91, 26, 53, 66, 67, 69, 70, and 
73. 
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Figure 15. Prevalence of ‘high-risk’ HPV (HR-HPV) among HIV negative. 
One patient can be infected with more than one HPV strain, hence adding up to more than 100 %.  The 
percentages were calculated as positive cases (including both single and multiple HPV infections) out of the total 
number of patients with HR-HPV infection in the HIV-positive group (n=7).  Other HR-HPV includes HPV31, 
33, 35, 39, 45, 51, 56, 58, 59, 68, 73, and 82.  
 
 
 
Figure 16. Prevalence (number of patients) of ‘high-risk’ HPV (HR-HPV) among HIV negative. 
One patient can be infected with more than one HPV strain. The total number of patients with HR-HPV infection 
in the HIV-negative group was 7, and the total number of HR-HPV infections was 8. Other HR-HPV includes 
HPV31, 33, 35, 39, 45, 51, 56, 58, 59, 68, 73, and 82.  
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Figure 17. Prevalence of ‘high-risk’ HPV (HR-HPV) among HIV positive.  
One patient can be infected with more than one HPV strain, hence adding up to more than 100 %.  The 
percentages were calculated as positive cases (including both single and multiple HPV infections) out of the total 
number of patients with HR-HPV infection in the HIV-positive group (n=36).  Other HR-HPV includes HPV33, 
35, 39, 45, 51, 56, 59, 68, 73, and 82.  
 
 
 
Figure 18. Prevalence (number of patients) of ‘high-risk’ HPV (HR-HPV) among HIV positive. 
One patient can be infected with more than one HPV strain. The total number of patients with HR-HPV infection 
in the HIV-positive group was 36, and the total number of HR-HPV infections was 41. Other HR-HPV includes 
HPV31, 33, 35, 39, 45, 51, 56, 58, 59, 68, 73, and 82.  
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